U.S. pharmaceutical giant Pfizer on Tuesday asked regulators to grant emergency use authorization for its COVID-19 pill after it was shown to cut hospitalization and death by nearly 90 percent among newly infected high-risk patients. Dr. Alice Hyun-Kyung Tan, an internist at MizMedi Women's Hospital in Seoul, shares her insight on the issue.
Copyright © 2020 CGTN. Beijing ICP prepared NO.16065310-3